Pharmaceuticals

Rhinovirus Infections Drug Market Forecast 2026–2035: How to Leverage Market Growth

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rhinovirus infections drug market from 2026–2035 with trusted insights from The Business Research Company

How much is the Rhinovirus Infections Drug Market valued at in 2026, and what valuation is forecast for 2030?

The market size for drugs treating rhinovirus infections has seen robust growth in recent years. It is anticipated to expand from $1.36 billion in 2025 to $1.48 billion by 2026, registering an 8.8% compound annual growth rate (CAGR). This historical growth can be attributed to the high prevalence of the common cold, limited antiviral treatment options, widespread usage of over-the-counter (OTC) drugs, typical seasonal infection patterns, and consumer demand for rapid relief.

The rhinovirus infections drug market size is anticipated to undergo significant growth in the coming years. It is projected to expand to $2.05 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.6%. The expansion during the forecast period is attributable to advances in antiviral research, improved viral targeting technologies, rising respiratory infection awareness, pediatric drug development, and innovation in nasal delivery. Prominent trends for the forecast period include rising research into antiviral cold treatments, a growing focus on symptom reduction therapies, expansion of nasal spray formulations, increased interest in immune-modulating drugs, and a shift toward preventive respiratory care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp

What Drivers Are Influencing The Growth Of The Rhinovirus Infections Drug Market?

A rising prevalence of respiratory ailments is projected to drive the expansion of the rhinovirus infections drug market in the foreseeable future. Respiratory disorders encompass medical conditions impacting the lungs and airways, leading to breathing difficulties, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The growth in respiratory disorders is primarily attributable to escalating air pollution and exposure to occupational hazards, resulting in conditions like asthma, COPD, and pneumonia, which are more frequently observed in affected populations. Rhinovirus infections drug assists in addressing respiratory disorders by targeting viral replication, diminishing inflammation, and alleviating symptoms to enhance respiratory function. For instance, in June 2025, as reported by the Office for Health Improvement & Disparities, a UK-based government agency, in the year ending 2024, England documented 854,922 emergency respiratory-related hospital admissions, equating to a rate of 1,428 per 100,000 people, signifying a 7% rise from the preceding year. Hence, the increasing occurrence of respiratory disorders fuels growth within the rhinovirus infections drug market.

What Segments Are Included Within The Rhinovirus Infections Drug Market?

The rhinovirus infections drug market covered in this report is segmented –

1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments

2) By Patient Age Group: Infants, Children, Adults, Elderly

3) By Route Of Administration: Oral, Intranasal, Injectable

4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

Subsegments:

1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals

2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines

4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays

5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines

What Trends Are Reshaping The Dynamics Of The Rhinovirus Infections Drug Market?

Leading firms within the rhinovirus infections drug market are concentrating on creating novel therapies, specifically antiviral medications, with the goal of improving treatment effectiveness, lessening the intensity of symptoms, and speeding up patient recovery. Antiviral medications combat viral infections by hindering the virus’s ability to multiply inside the body. Such drugs are effective in managing conditions like influenza, HIV, hepatitis, and rhinovirus infections. Certain antivirals work by preventing viruses from entering host cells, whereas others impede their replication or assembly processes. An example is Altesa BioSciences Inc., a biotechnology company based in the US, which in March 2025 obtained approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning vapendavir, intended for treating rhinovirus infections in individuals with COPD. Vapendavir functions as an oral broad-spectrum antiviral medication that stops rhinovirus from entering human cells and subsequently replicating. This drug has shown efficacy against 97% of rhinoviruses and various other respiratory enteroviruses. Altesa BioSciences possesses the sole global rights for the development, production, and commercialization of vapendavir. The medication is designed to offer specific treatment for at-risk populations, such as those suffering from COPD and asthma.

Who Are The Prominent Global Companies Shaping The Rhinovirus Infections Drug Market Landscape?

Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rhinovirus-infections-drug-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Rhinovirus Infections Drug Market?

North America was the largest region in the rhinovirus infection drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rhinovirus Infections Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23503&type=smp

Browse Through More Reports Similar to the Global Rhinovirus Infections Drug Market 2026, By The Business Research Company

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Acne Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Respiratory Syncytial Virus Rsv Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795